Initiator Pharma A/S (INIT.ST)
SEK 6.36
(1.92%)
SEK 6.36
(1.92%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 18.62 Million DKK | 30.04% |
| 2022 | 14.32 Million DKK | -23.44% |
| 2021 | 18.7 Million DKK | 1466.75% |
| 2020 | 1.19 Million DKK | -21.96% |
| 2019 | 1.53 Million DKK | 101.85% |
| 2018 | 758 Thousand DKK | -77.26% |
| 2017 | 3.33 Million DKK | 256.96% |
| 2016 | 934 Thousand DKK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 652 Thousand DKK | -96.5% |
| 2024 Q2 | 1.31 Million DKK | 101.23% |
| 2023 Q1 | 14.8 Million DKK | 3.34% |
| 2023 FY | 18.62 Million DKK | 30.04% |
| 2023 Q4 | 18.62 Million DKK | 6.03% |
| 2023 Q3 | 17.56 Million DKK | 2.18% |
| 2023 Q2 | 17.19 Million DKK | 16.16% |
| 2022 Q2 | 16.98 Million DKK | -4.9% |
| 2022 Q3 | 16.09 Million DKK | -5.26% |
| 2022 FY | 14.32 Million DKK | -23.44% |
| 2022 Q4 | 14.32 Million DKK | -11.02% |
| 2022 Q1 | 17.86 Million DKK | -4.51% |
| 2021 FY | 18.7 Million DKK | 1466.75% |
| 2021 Q2 | 3.72 Million DKK | 773.24% |
| 2021 Q3 | 15.28 Million DKK | 310.89% |
| 2021 Q4 | 18.7 Million DKK | 22.39% |
| 2021 Q1 | 426 Thousand DKK | -64.32% |
| 2020 Q2 | 2.07 Million DKK | 24.18% |
| 2020 Q3 | 698 Thousand DKK | -66.36% |
| 2020 FY | 1.19 Million DKK | -21.96% |
| 2020 Q4 | 1.19 Million DKK | 71.06% |
| 2020 Q1 | 1.67 Million DKK | 9.22% |
| 2019 Q2 | 2.48 Million DKK | 164.67% |
| 2019 FY | 1.53 Million DKK | 101.85% |
| 2019 Q3 | 4.83 Million DKK | 95.08% |
| 2019 Q4 | 1.53 Million DKK | -68.38% |
| 2019 Q1 | 937 Thousand DKK | 23.61% |
| 2018 Q1 | 1.79 Million DKK | -46.13% |
| 2018 FY | 758 Thousand DKK | -77.26% |
| 2018 Q4 | 758 Thousand DKK | -3.07% |
| 2018 Q3 | 782 Thousand DKK | -5.67% |
| 2018 Q2 | 829 Thousand DKK | -53.84% |
| 2017 Q1 | 437 Thousand DKK | -53.21% |
| 2017 Q4 | 3.33 Million DKK | 17.64% |
| 2017 Q3 | 2.83 Million DKK | 93.18% |
| 2017 FY | 3.33 Million DKK | 256.96% |
| 2017 Q2 | 1.46 Million DKK | 235.7% |
| 2016 Q4 | 934 Thousand DKK | 0.0% |
| 2016 FY | 934 Thousand DKK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Lipum AB (publ) | 7.53 Million SEK | -147.068% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 82.528% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -689.487% |
| BioArctic AB (publ) | 139.5 Million SEK | 86.65% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 46.178% |
| Mendus AB (publ) | 51.22 Million SEK | 63.643% |
| Genovis AB (publ.) | 98.04 Million SEK | 81.005% |
| CombiGene AB (publ) | 4.15 Million SEK | -348.123% |
| Intervacc AB (publ) | 21.68 Million SEK | 14.096% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 30.268% |
| Active Biotech AB (publ) | 13.4 Million SEK | -38.985% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 84.978% |
| Ziccum AB (publ) | 6.38 Million SEK | -191.547% |
| Camurus AB (publ) | 414.81 Million SEK | 95.51% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 69.646% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -15.555% |
| Aptahem AB (publ) | 8.99 Million SEK | -106.983% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 54.419% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 74.079% |
| Kancera AB (publ) | 17.97 Million SEK | -3.593% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 59.671% |
| Fluicell AB (publ) | 8.91 Million SEK | -108.906% |
| Saniona AB (publ) | 86.08 Million SEK | 78.365% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -261.07% |
| Biovica International AB (publ) | 34.76 Million SEK | 46.432% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -59.616% |
| AcouSort AB (publ) | 10.37 Million SEK | -79.457% |
| Xintela AB (publ) | 14.01 Million SEK | -32.886% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -35.235% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 96.137% |
| Abliva AB (publ) | 16.78 Million SEK | -10.983% |
| Corline Biomedical AB | 6.78 Million SEK | -174.326% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -60.982% |
| OncoZenge AB (publ) | 1.69 Million SEK | -996.174% |
| Amniotics AB (publ) | 10.54 Million SEK | -76.581% |
| 2cureX AB (publ) | 2.93 Million SEK | -534.549% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 91.322% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -320.786% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 98.811% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 2.818% |
| I-Tech AB | 16.2 Million SEK | -14.927% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 98.43% |
| Cyxone AB (publ) | 4.69 Million SEK | -296.762% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -39.736% |
| Biosergen AB | 5.08 Million SEK | -266.254% |
| Cantargia AB (publ) | 54.97 Million SEK | 66.12% |
| NextCell Pharma AB | 13.68 Million SEK | -36.05% |
| Nanologica AB (publ) | 79.32 Million SEK | 76.522% |
| SynAct Pharma AB | 51.83 Million SEK | 64.07% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -134.294% |
| LIDDS AB (publ) | 3.75 Million SEK | -395.847% |
| BioInvent International AB (publ) | 90.45 Million SEK | 79.41% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -156.529% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -258.502% |
| Alzinova AB (publ) | 9.33 Million SEK | -99.593% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -46.139% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 89.744% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -938.127% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -0.703% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -385.253% |
| Simris Alg AB (publ) | 148.93 Million SEK | 87.495% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 73.813% |